1010 related articles for article (PubMed ID: 23522150)
21. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
[TBL] [Abstract][Full Text] [Related]
22. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
23. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
24. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
25. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
29. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
30. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
[TBL] [Abstract][Full Text] [Related]
31. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
33. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.
Lai J; Yan Y; Mai L; Zheng YB; Gan WQ; Ke WM
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):154-9. PubMed ID: 23558069
[TBL] [Abstract][Full Text] [Related]
34. The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Wang X; Shen CH; Luo Y; Xin TY; Wang SY; Qiu DK
J Dig Dis; 2009 Nov; 10(4):321-7. PubMed ID: 19906113
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
[TBL] [Abstract][Full Text] [Related]
37. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
38. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
[TBL] [Abstract][Full Text] [Related]
39. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
40. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
